A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial
Author(s) -
Madhukar H. Trivedi,
Charles South,
Manish K. Jha,
A. John Rush,
Jing Cao,
Benji T. Kurian,
Mary L. Phillips,
Diego A. Pizzagalli,
Joseph M. Trombello,
María A. Oquendo,
Crystal Cooper,
Daniel G. Dillon,
Christian A. Webb,
Bruce D. Grannemann,
Gerard E. Bruder,
Patrick J. McGrath,
Ramin V. Parsey,
Myrna M. Weissman,
Maurizio Fava
Publication year - 2018
Publication title -
psychotherapy and psychosomatics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.531
H-Index - 98
eISSN - 1423-0348
pISSN - 0033-3190
DOI - 10.1159/000491093
Subject(s) - placebo , psychology , clinical trial , neuroticism , medicine , depression (economics) , clinical psychology , personality , social psychology , alternative medicine , economics , macroeconomics , pathology
One in three clinical trial patients with major depressive disorder report symptomatic improvement with placebo. Strategies to mitigate the effect of placebo responses have focused on modifying study design with variable success. Identifying and excluding or controlling for individuals with a high likelihood of responding to placebo may improve clinical trial efficiency and avoid unnecessary medication trials.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom